Astex Pharmaceuticals, Inc.
4140 Dublin Boulevard
About Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
• Fiscal strength with significant cash, ongoing revenues and potential milestone payments
• Productive partnerships with top-tier pharmaceutical companies
• Rich product portfolio with multiple drugs in clinical development
• Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.
282 articles with Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012
Astex Pharmaceuticals Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML
Astex Pharmaceuticals to Present at Biotechnology Industry Organization (BIO) Investor Forum on October 26th
Astex Pharmaceuticals Release: Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO
Astex Pharmaceuticals to Present at Jefferies and Co. Global Healthcare Conference on September 27th
SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Announces New Stock Ticker Symbol and New Website
SuperGen, Inc. to Present at Rodman & Renshaw Annual Healthcare Conference as Astex Pharmaceuticals, Inc. on September 12th